Gammanorm (human immune globulin subcutaneous) / Octapharma  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gammanorm (human immune globulin subcutaneous) / Octapharma
NCT03369301: The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

Completed
N/A
102
Europe
Gammanorm, Other Subcutaneous Immunoglobulins
Octapharma
Secondary Immune Deficiency
11/19
11/19
NCT03656640: Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases

Terminated
N/A
60
Europe, RoW
Gammanorm
Octapharma
Autoimmune Diseases
12/19
12/19
NCT04354129: Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.

Recruiting
N/A
30
Canada
Cutaquig®, Immunoglobulin (human) subcutaneous 16.5% Solution for injection (165 mg/mL)
University of Alberta, Octapharma
Primary Immune Deficiency Disorder, Secondary Immune Deficiency
06/24
06/24

Download Options